Endocrinol Metab.  2024 Aug;39(4):573-575. 10.3803/EnM.2024.2075.

For the Forthcoming Winning Shot in the Battle against Cushing Disease

• Chin SO

• KMID: 2558940
• DOI: http://doi.org/10.3803/EnM.2024.2075

Reference

1. Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S. An individualized approach to the management of Cushing disease. Nat Rev Endocrinol. 2023; 19:581–99.

2. Cushing H. The pituitary body and its disorders, clinical states produced by disorders of the hypophysis cerebri. London: JB Lippincott;1912.

3. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4:611–29.

4. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40:479–84.

5. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86:117–23.

6. Park JS, Yun SJ, Lee JK, Park SY, Chin SO. Descriptive epidemiology and survival analysis of prolactinomas and Cushing’s disease in Korea. Endocrinol Metab (Seoul). 2021; 36:688–96.

7. Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH. Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States. Pituitary. 2015; 18:283–9.

8. Ragnarsson O, Olsson DS, Chantzichristos D, Papakokkinou E, Dahlqvist P, Segerstedt E, et al. The incidence of Cushing’s disease: a nationwide Swedish study. Pituitary. 2019; 22:179–86.

9. The Korean Society of Endocrinology; The Survey Committee for Endocrine Diseases in Korea. The incidence and clinical characteristics of Cushing’s disease in Korea. Endocrinol Metab. 2000; 15:31–45.

10. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022; 43:1003–37.